Connect Biopharma director receives 5,000-share grant

The share count was based on the average closing price over the 30 days before September 30, 2026, rounded down to a whole share.

Rhea-AI Filing Summary

Connect Biopharma Holdings Ltd (CNTB) director Kleanthis Gabriel Xanthopoulos acquired 5,000 fully vested ordinary shares on September 30, 2026. The shares were granted under the Non-Employee Director Compensation Program in lieu of a portion of his cash compensation for 2026 annual board retainers, for director service during the third quarter of 2026. His direct holdings following the acquisition were 91,554 ordinary shares.

Insider Trade Summary

Grant/Award: 5,000 shares

Grant/Award 1 txn

Insider Xanthopoulos Kleanthis Gabriel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	5,000	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 91,554 shares (Direct)

Footnotes (1)

1. F1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.

Key Figures

Shares acquired: 5,000 ordinary shares Direct shares following transaction: 91,554 ordinary shares Price averaging period: 30 days

3 metrics

Shares acquired 5,000 ordinary shares Director compensation award on September 30, 2026

Direct shares following transaction 91,554 ordinary shares Following the September 30, 2026 acquisition

Price averaging period 30 days Period preceding September 30, 2026, used to calculate the share award

Key Terms

fully vested, Non-Employee Director Compensation Program, annual board retainers

3 terms

fully vested financial

"the fully vested ordinary shares were granted"

Non-Employee Director Compensation Program financial

"In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program"

annual board retainers financial

"cash compensation for his 2026 annual board retainers"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did the CNTB director receive?

Connect Biopharma director Kleanthis Gabriel Xanthopoulos received 5,000 fully vested ordinary shares on September 30, 2026, in lieu of a portion of cash compensation for his 2026 annual board retainers. The shares were granted for director service during the third quarter of 2026.

How did CNTB calculate the director's share award?

The number of shares was calculated by dividing the applicable value of the equity by the average closing price of Connect Biopharma ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 05:19 PM Accepted by SEC EDGAR 10/01/2026 - 05:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xanthopoulos Kleanthis Gabriel

(Last) (First) (Middle)

3580 CARMEL MOUNTAIN ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Connect Biopharma Holdings Ltd [ CNTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/30/2026		A		5,000(1)	A	$0	91,554	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.

Remarks:

	/s/ Lisa Peraza attorney-in-fact for Kleanthis Xanthopoulos	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)